Toward a national pharmaceuticals strategy

Toward a National Pharmaceuticals Strategy A summary of the 2006 health policy conference of the UBC Centre for Health Services and Policy Research May 2006 TOWARD A NATIONAL PHARMACEUTICALS STRATEGY: CONFERENCE SUMMARY 1 Toward a National Pharmaceuticals Strategy A summary of the 2006 health policy conference of the UBC Centre for Health Services and Policy Research was produced by: Centre for He [...] Sir Michael Rawlins chairs the National Institute for Health and Clinical Excellence (NICE), which provides national guidance on the promotion of good health and on the pre- vention and treatment of illness in the United Kingdom. [...] The CDR con- ducts a systematic review of the effectiveness of each new Dr Laupacis also noted the CDR is seeing more and more drug, which includes a critical review of a cost-effectiveness drugs that have been approved on the basis of surrogate submission from the drug company. [...] PHARMAC’s staff of 45 is pharmacy groups, and the pharmaceutical industry, on mandated to secure the best health outcomes possible for every decision made, by writing to each of the groups and the population of the island nation. [...] One of the key pieces of information that drug compa- nies are required to submit to PBAC is a comparative Under the National Health Act, Australia’s health care evaluation—a summary of how the new drug compares system is required to provide timely, reliable and af- with the drug or therapy it is intended to replace.